EUVIMED · CrossrefJournal
Clinical Pharmacokinetics
ISSN 0312-5963 · Springer Science and Business Media LLC
Latest articles
Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling
Pharmacokinetics and Pharmacodynamics of Antibiotics in Prostatitis and Lower Urinary Tract Infections in Men: A Critical Scoping Review of the Published Concentration Data
Multi-Objective Optimization of Population-Level Dosing Regimens
Comment on: “Population Pharmacokinetics of Intravenous Vitamin C in Adults with Sepsis: A Sub-Study of the LOVIT Trial”
Application of Pharmacometric Modelling Towards Precise Dosing in Neonates, Infants and Toddlers: A Scoping Review
Towards Model-Informed Precision Dosing of High-Dose Rifampicin: A Parsimonious Population Pharmacokinetic Model Capturing Saturation and Autoinduction in Tanzanian and South African Patients with Tuberculosis
Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors
The Variability in the Pharmacokinetics of Follitropin Alfa: A Systematic Review
From Clinical Trials to Real-World Patients: Population Pharmacokinetics and Precision Dosing Simulations of Lorlatinib
Metformin Pharmacogenetics in Heart Failure Patients with Reduced Ejection Fraction: Impact on Metformin and Growth Differentiation Factor-15 Plasma Levels
Optimization of Cefotaxime Treatment in Intensive Care Patients: Impact of Inter- and Intra-patient Variability on Pharmacokinetics and Target Attainment
Comparing the Predictive Performance of Machine Learning Models with a Newly Developed Population Pharmacokinetic Model for Busulfan in Paediatric Patients
PBPK Modeling of Coproporphyrin I Reveals Frailty-Associated Changes in Hepatic OATP1B1 Function in Chinese Adults
A Patient-Centered Approach for Drug–Drug Interaction (DDI) Assessment: Integrating Nested Clinical DDI Studies to Verify Translatability of Healthy Volunteer DDI Data, Minimize Stand-Alone Trials, and Enrich Drug Labeling
Safety, Pharmacokinetics, and Pharmacodynamics of SHR-2004, a Novel Humanized Monoclonal Antibody Targeting Factor XI, in Patients with Atrial Fibrillation: An Open-Label Phase 1b Study
Microbiome-Mediated Pharmacokinetics and Informed Dosing of Mycophenolate in Kidney Transplantation
Transitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administration
A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics
Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer
Population Pharmacokinetics of Intravenous Vitamin C in Adults with Sepsis: A Sub-study of the LOVIT Trial
Blood Never Lies: The PopPK-Based Lie Detector
Correction: Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28‑Joint C‑Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis
ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma
Elranatamab Population Pharmacokinetics and Exposure–Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma
Physiologically Based Pharmacokinetic (PBPK) Modeling of Antidepressants: A Scoping Review of Existing Models, Applications, and Software Tools
How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis
Correction: Population Pharmacokinetic Analysis of Enalapril and Enalaprilat in Newly Treated Children with Heart Failure: Implications for Safe Dosing of Enalapril (LENA Studies)
Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection
Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness
Volumes
2026 · 1342025 · 1312024 · 1282023 · 1312022 · 1322021 · 1252020 · 1242019 · 1272018 · 1242017 · 1252016 · 1142015 · 1112014 · 912013 · 812012 · 682011 · 652010 · 592009 · 612008 · 632007 · 692006 · 832005 · 882004 · 742003 · 832002 · 902001 · 742000 · 671999 · 771998 · 581997 · 761996 · 671995 · 941994 · 741993 · 901992 · 961991 · 761990 · 721989 · 811988 · 511987 · 47
EUVIMED